Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 14/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28183980 | 0.93 | MAOB (0.51) | MAOBNPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL31314554 | 0.88 | MAOB (0.50) | MAOBNPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4974849 | 0.87 | MAOB (0.72) | MAOBNPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL30643084 | 0.87 | MAOB (0.72) | MAOBNPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL8761733 | 0.83 | MAOB (0.61) | MAOBNPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL70456 | 0.82 | MAOB (0.76) | MAOBNPC1MAPTRAB9AADORA2B | |
| SCHEMBL5158204 | 0.80 | MAOB (0.50) | MAOBNPC1MAPTRAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL87683 | 0.80 | MAOB (0.73) | MAOBNPC1MAPTRAB9AADORA2B | |
| SCHEMBL1299217 | 0.80 | MAOB (0.58) | MAOBNPC1MAPTRAB9AADORA2B | |
| SCHEMBL9953047 | 0.80 | MAOB (0.49) | MAOBNPC1MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2026-03-12 | — | — | US | claimed |
| WO-2025224601-A1 | TRPM3 ANTAGONISTS FOR THE TREATMENT OF MIGRAINE AND PAIN | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-10-30 | — | — | WO | claimed |
| WO-2025111414-A1 | TRPM3-MODULATING BENZOFURAN DERIVATIVES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-05-30 | — | — | WO | claimed |
| EP-4532479-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-04-09 | — | — | EP | claimed |
| WO-2024261504-A1 | BENZOFURAN-3-CARBOXYLIC ACID AMIDES AND BENZOFURAN-3- CARBONYL-BENZAMIDES, METHOD FOR THEIR PRODUCTION WITH HIGH SELECTIVITY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PÉCSI TUDOMÁNYEGYETEM (HU) | 2024-12-26 | — | — | WO | claimed |
| CN-117836306-A | Galactose glycoside derivatives as galectin-3 inhibitors | 株式会社蒂奥姆生物 | 2024-04-05 | — | — | CN | claimed |
| US-20240051949-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2024-02-15 | — | — | US | claimed |
| CN-114751883-B | Preparation method of benzofuran-3-carboxamide compound | 浙江理工大学 | 2024-01-16 | — | — | CN | claimed |
| WO-2023227695-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | claimed |
| CN-116745283-A | Heterocyclic derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2023-09-12 | — | — | CN | claimed |
| US-7994171-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-09 | — | — | US | claimed |
| US-20100249094-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-30 | — | — | US | claimed |
| JP-2007516273-A | — | — | 2007-06-21 | — | — | JP | claimed |
| EP-1699780-A1 | NOVEL QUINOLINE DERIVATIVES | Pfizer, Inc. (US) | 2006-09-13 | — | — | EP | claimed |
| WO-2005063739-A1 | NOVEL QUINOLINE DERIVATIVES | PFIZER INC. (US) | 2005-07-14 | — | — | WO | claimed |
| US-5442077-A | Benzo[B]Furancarboxamide derivatives, process for the preparation of same and use thereof for improving hypermotility | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1995-08-15 | — | — | US | claimed |
| EP-0640602-A1 | Benzo[b]furancarboxamide derivatives, process for their preparation and their use as gastrointestinal mobility-enhancing agents | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1995-03-01 | — | — | EP | claimed |
| EP-0045473-B1 | A PHARMACEUTICAL COMPOSITION CONTAINING A BENZOFURAN-CARBOXAMIDE DERIVATIVE AS THE ACTIVE INGREDIENT | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1984-05-02 | — | — | EP | claimed |
| US-4353923-A | MUSCLE RELAXANTS, ANTIINFLAMMATORY, ANALGESIC | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1982-10-12 | — | — | US | claimed |
| EP-0045473-A1 | A pharmaceutical composition containing a benzofuran-carboxamide derivative as the active ingredient | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1982-02-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249094-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | MAOB 748/4885NPC1 31/4885MAPT 4242/4885 |
| US-20240051949-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM4, TRPM6, TRPM2 | MAOB 1881/4885NPC1 535/4885MAPT 2911/4885 |
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM6, TRPV3, TRPM2 | MAOB 1863/4885NPC1 760/4885MAPT 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.